Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination of Standard Chemotherapy and Targeted Agents

Combination of Standard Chemotherapy and Targeted Agents PISA SYMPOSIUM Combination of Standard Chemotherapy and Targeted Agents Maria Anna Bareschino, MD, Floriana Morgillo, MD, and Fortunato Ciardiello, MD (J Thorac Oncol. 2007;2: Suppl 1, 19–23) (EGFR) axis have demonstrated survival benefits in prospec- tive, randomized, phase 3 clinical trials. These studies have established bevacizumab and erlotinib as agents with an efore the introduction of novel molecularly targeted ther- emerging role in the treatment of many patients with ad- Bapies, results with a wide range of chemotherapy regi- vanced NSCLC. mens for patients with advanced non-small cell lung cancer In light of the encouraging results achieved with EGFR (NSCLC) had reached a plateau beyond which improved tyrosine kinase inhibitors (TKIs) and other targeted ap- efficacy seemed unlikely. proaches in the salvage setting, multiple prospective random- Multiple trials over the last several years have demon- ized clinical trials have tested platinum-based doublet che- strated the generally equivalent efficacy of a number of motherapy with or without a novel targeted approach, seeking doublet chemotherapy regimens for first-line treatment of a statistically and clinically significant survival benefit. Sev- advanced/metastatic NSCLC. Results reported by the Eastern eral novel treatment approaches have generated negative Cooperative Oncology Group (ECOG) 1594 study and other results http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Combination of Standard Chemotherapy and Targeted Agents

Loading next page...
 
/lp/wolters-kluwer-health/combination-of-standard-chemotherapy-and-targeted-agents-4VMIevaTXW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

PISA SYMPOSIUM Combination of Standard Chemotherapy and Targeted Agents Maria Anna Bareschino, MD, Floriana Morgillo, MD, and Fortunato Ciardiello, MD (J Thorac Oncol. 2007;2: Suppl 1, 19–23) (EGFR) axis have demonstrated survival benefits in prospec- tive, randomized, phase 3 clinical trials. These studies have established bevacizumab and erlotinib as agents with an efore the introduction of novel molecularly targeted ther- emerging role in the treatment of many patients with ad- Bapies, results with a wide range of chemotherapy regi- vanced NSCLC. mens for patients with advanced non-small cell lung cancer In light of the encouraging results achieved with EGFR (NSCLC) had reached a plateau beyond which improved tyrosine kinase inhibitors (TKIs) and other targeted ap- efficacy seemed unlikely. proaches in the salvage setting, multiple prospective random- Multiple trials over the last several years have demon- ized clinical trials have tested platinum-based doublet che- strated the generally equivalent efficacy of a number of motherapy with or without a novel targeted approach, seeking doublet chemotherapy regimens for first-line treatment of a statistically and clinically significant survival benefit. Sev- advanced/metastatic NSCLC. Results reported by the Eastern eral novel treatment approaches have generated negative Cooperative Oncology Group (ECOG) 1594 study and other results

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2007

There are no references for this article.